BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15831697)

  • 41. FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia.
    Schnittger S; Schoch C; Kern W; Hiddemann W; Haferlach T
    Acta Haematol; 2004; 112(1-2):68-78. PubMed ID: 15179006
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NPM and NPM-MLF1 interact with chromatin remodeling complexes and influence their recruitment to specific genes.
    Darracq A; Pak H; Bourgoin V; Zmiri F; Dellaire G; Affar EB; Milot E
    PLoS Genet; 2019 Nov; 15(11):e1008463. PubMed ID: 31675375
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
    Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
    Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent.
    Chan N; Lim TM
    Sci Rep; 2015 Jun; 5():11777. PubMed ID: 26123729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Absence of nucleophosmin leukaemic mutants in B and T cells from AML with NPM1 mutations: implications for the cell of origin of NPMc+ AML.
    Martelli MP; Manes N; Pettirossi V; Liso A; Pacini R; Mannucci R; Zei T; Bolli N; di Raimondo F; Specchia G; Nicoletti I; Martelli MF; Falini B
    Leukemia; 2008 Jan; 22(1):195-8. PubMed ID: 17637812
    [No Abstract]   [Full Text] [Related]  

  • 46. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia.
    Christiansen DH; Andersen MK; Desta F; Pedersen-Bjergaard J
    Leukemia; 2005 Dec; 19(12):2232-40. PubMed ID: 16281072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
    Drexler HG
    Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
    Goemans BF; Zwaan CM; Miller M; Zimmermann M; Harlow A; Meshinchi S; Loonen AH; Hählen K; Reinhardt D; Creutzig U; Kaspers GJ; Heinrich MC
    Leukemia; 2005 Sep; 19(9):1536-42. PubMed ID: 16015387
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
    Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
    Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Differential expression of the RET gene in human acute myeloid leukemia.
    Gattei V; Degan M; Aldinucci D; De Iuliis A; Rossi FM; Mazzocco FT; Rupolo M; Zagonel V; Pinto A
    Ann Hematol; 1998 Nov; 77(5):207-10. PubMed ID: 9858145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nucleophosmin mutation analysis in acute myeloid leukaemia: Immunohistochemistry as a surrogate for molecular techniques.
    Chopra A; Soni S; Pati H; Kumar D; Diwedi R; Verma D; Vishwakama G; Bakhshi S; Kumar S; Gogia A; Kumar R
    Indian J Med Res; 2016 Jun; 143(6):763-768. PubMed ID: 27748301
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cytoplasmic localization of NPM in myeloid leukemias is dictated by gain-of-function mutations that create a functional nuclear export signal.
    Mariano AR; Colombo E; Luzi L; Martinelli P; Volorio S; Bernard L; Meani N; Bergomas R; Alcalay M; Pelicci PG
    Oncogene; 2006 Jul; 25(31):4376-80. PubMed ID: 16501600
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
    Robinson LJ; Xue J; Corey SJ
    Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication.
    Kussick SJ; Stirewalt DL; Yi HS; Sheets KM; Pogosova-Agadjanyan E; Braswell S; Norwood TH; Radich JP; Wood BL
    Leukemia; 2004 Oct; 18(10):1591-8. PubMed ID: 15343344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.
    Chillón MC; Fernández C; García-Sanz R; Balanzategui A; Ramos F; Fernández-Calvo J; González M; Miguel JF
    Hematol J; 2004; 5(3):239-46. PubMed ID: 15167911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations.
    Cilloni D; Messa F; Rosso V; Arruga F; Defilippi I; Carturan S; Catalano R; Pautasso M; Panuzzo C; Nicoli P; Messa E; Morotti A; Iacobucci I; Martinelli G; Bracco E; Saglio G
    Leukemia; 2008 Jun; 22(6):1234-40. PubMed ID: 18401421
    [TBL] [Abstract][Full Text] [Related]  

  • 59. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic significance of FLT3 ITD and D835 mutations in AML patients.
    Sheikhha MH; Awan A; Tobal K; Liu Yin JA
    Hematol J; 2003; 4(1):41-6. PubMed ID: 12692519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.